[1]
|
D. J. Betteridge, “What is Oxidative Stress?” Metabolism, Vol. 49, No.2, 2000, pp. 3-8.
|
[2]
|
B. Halliwell, “Free radicals, Antioxidants & Human Disease: Curiosity, Cause or Consequence,” Lancet, Vol. 344, No. 8924, 1994, pp. 721-724.
|
[3]
|
K. Kannan and S. K. Jain, “Oxidative Stress & Apoptosis,” Pathophysiology, Vol. 7, No. 3, 2000, pp. 153-163.
|
[4]
|
S. Shah, M. Iqbal, J. Karam, M. Salifu and S. I. Mcfarlane, “Oxidative stress, Glucose Metabolism & the Prevention of Ttype 2 Diabetes: Pathophyiological Insights,” Antioxidants & Rredox Signaling, Vol. 9, No. 7, 2007, pp. 911-929.
|
[5]
|
I. S. Young and J. V. Woodside, “Antioxidants in Health & Disease,” Journal of Clinical Pathology, Vol. 54, No. 3, 2001, pp. 176-186.
|
[6]
|
J. A. Florence and B. F Yeager, “Treatment of Type 2 Diabetes Mellitus,” American Family Physician, Vol. 59, 1999, p. 10.
|
[7]
|
J. L. Mehta, N. Rasouli, A. K. Sinha and B. Molavi, “Oxidative Stress in Diabetes: A mechanistic Overview of its Effects on Atherogenesis and Myocardial Dysfunction,” The International Journal of Biochemistry & Cell Biology, Vol. 38, No. 5-6, June 2006, pp. 794-803.
|
[8]
|
L. W. Oberley, “Free Radicals and Diabetes,” Free Radical Biology & Medicine, Vol. 5, No. 2, 1988, pp. 113- 124.
|
[9]
|
N. Eisei and T. Hirokazu, “Parameters for Measurement of Oxidative Stress in Diabetes Mellitus: Applicability of ELISA for Clinical Evaluation,” Jòurnal of Investigation Medicine, Vol. 53, No.4, May 2005, pp. 167-175.
|
[10]
|
J. S. Johansen, A. K. Harris, D. J. Rychly and A. Ergul, “Oxidative Stress & the Use of Antioxidants in Diabetes: Linking Basic Science to Clinical Practice,” Cardiovascular Diabetology, Vol. 4, April 2005, p. 5.
|
[11]
|
J. Patel, “Dyslipidaemia in Diabetes,” British Midical Journal Clinical Evidence, Vol. 8, No. 4, 2006, pp. 355- 364.
|
[12]
|
C. M. Florkowski, “Management of Co-Existing Diabetes Mellitus & Dyslipidaemia: Defining the Role of Thiazolidinediones,” American Journal of Cardiovascular Drugs, Vol. 2, No. 1, 2002, pp. 15-21.
|
[13]
|
F. Violi, L. Loffredo, L. Musella and A. Marcoccia, “Should Antioxidant Status be Considered in Interventional Trials with Antioxidants?” Heart, Vol. 90, No. 6, 2004, pp. 598-602.
|
[14]
|
M. C. Sheffield, “Multiple Effects of Statins in Non Lipid Disease States,” US Pharmacist, Vol. 6, 2004, pp. 38-54.
|
[15]
|
J. K. Liao, “Isoprenoids as Mediators of the Biological Effects of Statins,” Journal Clinical Investigation, Vol. 110, No. 3, August 2002, pp. 285-288.
|
[16]
|
F. R. Danesh and Y. S. Kanwar, “Modulatory Effects of HMG-CoA Reductase Inhibitors in Diabetic Microangiopathy,” The FASEB Journal, Vol. 18, No. 7, 2004, pp. 805-815.
|
[17]
|
J. Beltowski, “Statins & Modulation of Oxidative Stress,” Toxicology Mechanisms & Methods, Vol. 15, No. 2, 2005, pp. 61-92.
|
[18]
|
B. B. Hodgson and R. J. Kizior, “Saunders Nursing Drug Handbook,” Jones and Bartlett, Boston, 2003.
|
[19]
|
A. Heerey, M. Barry, M. Ryan and A. Kelly, “The Potential for Drug Interactions with Statin Therapy in Iraland,” Irish Journal of Medical Science, Vol. 169, No. 3, 2001, pp. 176-179.
|
[20]
|
A. J. Ellsworth, D. M. Witt, D. C. Dugdale and L. M. Oliver, “Mosby,s Medical Drug Reference,” 2003.
|
[21]
|
R. S. Munford, “Statins & the Acute Phase Response,” New England Journal of Medicine, Vol. 344, No. 26, June 2001, pp. 2016-2018.
|
[22]
|
M. H. Shishehbor, M. L. Brennan, R. J. Aviles, X. Fu, M. S. Penn, D. L. Sprecher and S. L. Hazen, “Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory pathways,” Circulation, Vol. 108, No. 4, 2003, pp. 426-431.
|
[23]
|
T. Vishal, G. Bano, V. Khajuria, A. Parihar and S. Gupta, “Pleiotropic Effects of Statins,” Indian Journal Pharmacology, Vol. 37, No. 2, 2005, pp. 77-85.
|
[24]
|
M. E. Marketou, E. A. Zacharis, D. Nikitovic, E. S. Ganotakis, F. I. Parthenakis and N. Maliaraki, “Early Effects of Simvastatin Versus Atorvastatin on Oxidative Stress Proinflammatory Cytokines in Hyperlipidaemic Subjects,” Angiology, Vol. 57, No. 2, March 2006, pp. 211-218.
|
[25]
|
V. V. Uzunova, A. N. Tolekova, G. S. IIieva and A. P. Trifonova, “Renin-Angiotensin System & Lipid Peroxidation,” Bulgarian Journal of Veterinary Medicine, Vol. 1, 2005, pp. 69-75.
|
[26]
|
B. I. Kasiske, J. Z. Ma, R. S. Kalil and T. A Louis, “Effects of Antihypertensive Therapy on serum lipids,” Annals of Internal Medicine, Vol. 122, No. 2, January 1995, pp. 133-141.
|
[27]
|
N. Kebapci, B. Efe, F. Akyuz, E. Sunal and C. Demirustu, “Oxidative Stress & Antioxidant Therapy in Type 2 Diabetes Mellitus,” Turkish Journal of Endocrinology & Metabolism, Vol. 4, 1999, pp. 153-162.
|
[28]
|
G. L. Ellman, “Tissue Sulfhydyl Groups,” Archives of Biochemistry and Biophys, Vol. 82, No. 1, May 1959, pp. 70-77.
|
[29]
|
B. Guidet and S. V. Shah, American Journal of Physiology, Vol. 257, No. 26, 1989, p. 440.
|
[30]
|
W. H. Michael, M. J. Pabst and W. B. Jakoby, “Glutathione-S-Transferase. The First Enzymatic Step in Mercapturic Acid Formation,” Journal of Biological Chemistry, Vol. 22, No. 25, 1974, pp. 7130-7139.
|
[31]
|
H. Aebi, In Methods of Enzymatic Analysis, H.U. Bergme-tered, ed, New York, Academic press 1974, Vol, 2, pp. 674-678.
|
[32]
|
W.T. Friedewald, R.I. Levy and D.S. Fredrickson, “Estimation of the Concentration of LDL-C in Plasma without Use the Preparative Ultracentrifuge,” Clinical Chemistry, Vol. 18, No. 6, Jun 1972, 499-502.
|
[33]
|
V. Save, N. Patil, N, Moulik and G. Rajadhyaksha, “Effect of Atorvastatin on Type 2 Diabetic Dyslipidaemia,” Journal of Cardiovascular Pharmacololgy & Therapeutics, Vol. 11, No. 4, December 2006, pp. 262-270.
|
[34]
|
M. Koter, M. Broncel, J. Chjnowska-Jezierska, K. Klikczynska and I. Franiak, “The Effect of Atorvastatin on Erythrocyte Membranes & Serum Lipids in Patients with Type 2 Hypercholesterolaemia,” European Journal of Clinical Pharmacology, Vol. 58, No. 8, 2002, pp. 501-506.
|
[35]
|
J.K. Liao and U. Laufs, “Pleiotropic Effects of Statins,” Annual Review Pharmacology & Toxicology, Vol. 45, Febreuary 2005, pp. 89-118.
|
[36]
|
J. C. Mason, “Statins & Their Role in Vascular Protection,” Clinical Science, Vol. 105, 2003, pp. 251-266.
|
[37]
|
S. Passi, A. Stancato, E. Aleo, A. Dmitrieva and G.P. Littarru, “Statins Lower Plasma & Lymphocyte Ubiquinol Ubiquinone Without Affecting Other Antioxidants & PUFA,” Biofactors, Vol. 18, No. 1-4, 2003, 113-124.
|
[38]
|
S. Wassmann, U. Laufs, K. Muller, C. Konkol, K. Ahlbory and .T. Baumer, et al, “Cellular Antioxidant Effects of Atorvastatin in Vitro & in Vivo,” Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 22, 2002, pp. 300-305.
|
[39]
|
DALI Study Group, “The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidaemia: the DALI Study: A double Blind Randomized Placeb Controlled Trial in Patients with Type 2 Diabetes & Diabetic Dyslipidaemia,” Diabetes Care,Vol. 24, No. 8, 2001, pp. 1335-1341.
|
[40]
|
M. Alegret and J.S. Silvestre, “Pleiotropic Effects of Statins & Related Pharmacological Experimental Approaches,” Methods and Finding Experimental Clinical Pharmacology, Vol. 28, No.9, 2006, pp. 627.
|
[41]
|
K. Sakabe, N. Fukuda, K. Wakayama, T. Nada, H. Shinohara and Y. Tamura “Effects of Atorvastatin Therapy on the Low - Density Lipoprotein Subfraction, Remnant-Like Particles Cholesterol, and Oxidized Low-Density Lipoprotein within 2 Weeks in Hypercholesterolemic Patients,” Circulation Journal, Vol. 67, No. 10, 2003, pp. 866-870.
|
[42]
|
U. Laufs and J.K. Liao, “Isoprenoid Metabolism & the Pleiotropic Effects of Statins,” Current Atherosclerosis Reports, Vol. 5, No.5, 2003, pp. 372-378.
|